Our Promise to you:
Premier global microbiological solutions, extensive collection of products.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Kidney cancer also called renal cell carcinoma (RCC), is a highly vascular tumor in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Targeted therapy drugs target specific functions or genes that play a significant role in the development of cancer. They intervene the functions that are necessary for cancer to survive and grow.
Fig.1 Biological pathways and therapeutic targeted agents for renal cell carcinoma.
Targeted cancer drugs work by targeting specific genes and proteins in cancer cells that help them to grow and survive. Targeted therapy drugs which are generally available for kidney cancer are listed below.
|Target||Types||Agent||Manufacturer||Start Marketing Date|
|IL2RA, IL2RB, IL2RG||Peptide immunopotentiator||Proleukin||CHIRON||1992|
|VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, c-KIT||Small molecule||Inlyta||Pfizer||2012|
|c-MET, VEGFR-2, FLT-3, c-KIT, RET||Small molecule||Cabometyx||Exelixis||2016|
|mTOR||Small molecule||Certican Afinitor Zortress||Novartis||2009|
|RTK/FLT1, KDR, FLT4, FGFR1, FGFR2, FGFR3, PDGFRB||Small molecule||Lenvima||ESAL||2015|
|VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, FGFR, c-KIT||Small molecule||Votrient||Novartis||2009|
|KIT, VEGFR, PDGFR, RAF||Small molecule||Nexavar||Bayer||2005|
|VEGFR, PDGFR, KIT||Small molecule||Sutent||Pfizer||2006|
|mTOR||Small molecule||Torisel||PF Prism CV||2007|
As a novel delivery system, bacterial were conceived as potential cancer therapeutics. We are committed to providing oncolytic bacteria genome editing service to best meet your research goals, with reduced turnaround time and lower prices. If you have any question, please feel free to contact us at firstname.lastname@example.org. We will propose the best strategy for you.
• Fast turnaround time, lower price
• higher efficiency and success rate
• Rich experience
• Markerless genome editing
• Easy selection: no selectable marker is required
1. Cho, I. C. , & Chung, J. . (2012). Current status of targeted therapy for advanced renal cell carcinoma. Korean journal of urology, 53(4), 217-228.